Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $229,020.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.34, for a total transaction of $229,020.00. Following the completion of the sale, the chief operating officer now directly owns 210,503 shares of the company’s stock, valued at $16,069,799.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, June 3rd, Jim Wassil sold 3,000 shares of Vaxcyte stock. The shares were sold at an average price of $71.99, for a total transaction of $215,970.00.

Vaxcyte Stock Up 0.3 %

NASDAQ PCVX opened at $76.26 on Friday. Vaxcyte, Inc. has a 1 year low of $44.20 and a 1 year high of $82.04. The company has a fifty day simple moving average of $70.84 and a 200 day simple moving average of $68.34.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. On average, sell-side analysts expect that Vaxcyte, Inc. will post -3.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Needham & Company LLC reiterated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a research note on Friday, June 28th.

Hedge Funds Weigh In On Vaxcyte

Large investors have recently made changes to their positions in the business. Northern Trust Corp increased its position in Vaxcyte by 4.1% in the 3rd quarter. Northern Trust Corp now owns 896,635 shares of the company’s stock worth $45,710,000 after buying an additional 35,694 shares during the period. Glenmede Trust Co. NA acquired a new stake in shares of Vaxcyte in the third quarter worth $762,000. Alps Advisors Inc. increased its position in Vaxcyte by 0.6% during the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company’s stock worth $3,533,000 after acquiring an additional 426 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in Vaxcyte by 119.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 132,088 shares of the company’s stock valued at $6,734,000 after purchasing an additional 72,000 shares during the last quarter. Finally, Sectoral Asset Management Inc. boosted its holdings in Vaxcyte by 11.2% in the 3rd quarter. Sectoral Asset Management Inc. now owns 121,230 shares of the company’s stock valued at $6,180,000 after purchasing an additional 12,253 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.